FDA 483 - Moore Clinical Research Inc. - March 05, 2015

During an inspection of Moore Clinical Research Inc. in Brandon, FL, the FDA observed a significant protocol deviation at this biopharmaceuticals clinical facility. An investigation was not conducted in accordance with the investigational plan, specifically regarding subject enrollment criteria. A subject was consented and randomized into a study despite being underage according to the protocol's inclusion criteria.